{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:34:30Z","timestamp":1773336870814,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00120-026-02774-y","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T15:14:57Z","timestamp":1770390897000},"page":"264-270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvante Therapie und komplettes Ansprechen beim muskelinvasiven Urothelkarzinom: Darf die Harnblase erhalten werden?","Neoadjuvant therapy and complete response of muscle-invasive bladder cancer: may the urinary bladder be preserved?"],"prefix":"10.1007","volume":"65","author":[{"given":"Christian","family":"Bolenz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friedemann","family":"Zengerling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"K\u00fcbler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"2774_CR1","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, Awmf) (2025) S3-Leitlinie Fr\u00fcherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms. In: https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/harnblasenkarzinom\/; Zugriff am 12.12.2025."},{"key":"2774_CR2","doi-asserted-by":"crossref","unstructured":"Van Der Heijden AG, Bruins HM, Carrion A et\u00a0al. (2025) European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines. Eur Urol 87:582\u2013600","DOI":"10.1016\/j.eururo.2025.02.019"},{"key":"2774_CR3","doi-asserted-by":"crossref","unstructured":"Paffenholz P, Zschabitz S (2024) [Classical chemotherapy, immunotherapy, or adjuvant radiotherapy-how to improve the oncologic outcome of radical cystectomy?]. Urologie 63:994\u20131001","DOI":"10.1007\/s00120-024-02433-0"},{"key":"2774_CR4","doi-asserted-by":"crossref","unstructured":"Chua KJ, Patel HV, Srivastava A et\u00a0al. (2023) Annual trends of cystectomy complications: A\u00a0contemporary analysis of the NSQIP database. Urol Oncol 41:390 e319-390 e326","DOI":"10.1016\/j.urolonc.2023.03.014"},{"key":"2774_CR5","doi-asserted-by":"crossref","unstructured":"Maibom SL, Joensen UN, Poulsen AM et\u00a0al. (2021) Short-term morbidity and mortality following radical cystectomy: a\u00a0systematic review. BMJ Open 11:e043266","DOI":"10.1136\/bmjopen-2020-043266"},{"key":"2774_CR6","doi-asserted-by":"crossref","unstructured":"Hausmann J, Grunewald CM (2024) [Can muscle invasive bladder cancer be treated without cystectomy in the future? : New data on trimodal therapy and bladder preservation after systemic therapy alone]. Urologie 63:985\u2013993","DOI":"10.1007\/s00120-024-02420-5"},{"key":"2774_CR7","doi-asserted-by":"crossref","unstructured":"Schlack K (2023) [Perioperative systemic treatment of urothelial cancer]. Urologie 62:407\u2013417","DOI":"10.1007\/s00120-023-02061-0"},{"key":"2774_CR8","doi-asserted-by":"crossref","unstructured":"Galsky MD, Daneshmand S, Izadmehr S et\u00a0al. (2023) Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a\u00a0phase\u00a02\u00a0trial. Nat Med 29:2825\u20132834","DOI":"10.1038\/s41591-023-02568-1"},{"key":"2774_CR9","doi-asserted-by":"crossref","unstructured":"Gupta S, Hensley PJ, Li R et\u00a0al. (2026) Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group. Eur Urol 89:18\u201328","DOI":"10.1016\/j.eururo.2025.03.017"},{"key":"2774_CR10","doi-asserted-by":"crossref","unstructured":"Ghatalia P, E.A. R, Zibelman MR et\u00a0al. (2025) A phase\u00a02\u00a0trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2). In: 2025 ASCO Genitourinary Cancers Symposium. Journal of Clinical Oncology, p\u00a0815","DOI":"10.1200\/JCO.2025.43.5_suppl.815"},{"key":"2774_CR11","doi-asserted-by":"crossref","unstructured":"Yin M, Joshi M, Meijer RP et\u00a0al. (2016) Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A\u00a0Systematic Review and Two-Step Meta-Analysis. Oncologist 21:708\u2013715","DOI":"10.1634\/theoncologist.2015-0440"},{"key":"2774_CR12","doi-asserted-by":"crossref","unstructured":"Heidenreich A, Bohmer D, Bolenz C et\u00a0al. (2025) New Bladder Preservation Strategies in Urothelial Carcinoma of the Bladder. Dtsch Arztebl Int 122:211\u2013218","DOI":"10.3238\/arztebl.m2025.0014"},{"key":"2774_CR13","doi-asserted-by":"crossref","unstructured":"Zlotta AR, Ballas LK, Niemierko A et\u00a0al. (2023) Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a\u00a0multi-institutional propensity score matched and weighted analysis. Lancet Oncol 24:669\u2013681","DOI":"10.1016\/S1470-2045(23)00170-5"},{"key":"2774_CR14","doi-asserted-by":"crossref","unstructured":"Hoimes CJ, Flaig TW, Milowsky MI et\u00a0al. (2023) Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. J\u00a0Clin Oncol 41:22\u201331","DOI":"10.1200\/JCO.22.01643"},{"key":"2774_CR15","doi-asserted-by":"crossref","unstructured":"Powles T, Catto JWF, Galsky MD et\u00a0al. (2024) Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. N Engl J Med 391:1773\u20131786","DOI":"10.1056\/NEJMoa2408154"},{"key":"2774_CR16","doi-asserted-by":"crossref","unstructured":"Mannion L, Watson V, Mullassery V et\u00a0al. (2024) Treatment preferences of patients with muscle invasive bladder cancer: A\u00a0discrete choice experiment. BJUI Compass 5:1059\u20131068","DOI":"10.1002\/bco2.443"},{"key":"2774_CR17","doi-asserted-by":"crossref","unstructured":"Collacott H, Soekhai V, Thomas C et\u00a0al. (2021) A Systematic Review of Discrete Choice Experiments in Oncology Treatments. Patient\u00a014:775\u2013790","DOI":"10.1007\/s40271-021-00520-4"},{"key":"2774_CR18","doi-asserted-by":"crossref","unstructured":"Geynisman DM, Abbosh PH, Ross E et\u00a0al. (2025) Phase\u00a0II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN\u00a01). J\u00a0Clin Oncol 43:1113\u20131122","DOI":"10.1200\/JCO-24-01214"},{"key":"2774_CR19","doi-asserted-by":"crossref","unstructured":"Kaur J, Choi W, Geynisman DM et\u00a0al. (2021) Role of immunotherapy in localized muscle invasive urothelial cancer. Ther Adv Med Oncol 13:17588359211045858","DOI":"10.1177\/17588359211045858"},{"key":"2774_CR20","doi-asserted-by":"crossref","unstructured":"Li R, Nocera L, Rose KM et\u00a0al. (2024) Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer. Eur Urol Oncol 7:614\u2013624","DOI":"10.1016\/j.euo.2023.12.008"},{"key":"2774_CR21","doi-asserted-by":"crossref","unstructured":"Ungaro A, Tucci M, Audisio A et al. (2022) Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside. Cells 11(5)","DOI":"10.3390\/cells11050803"},{"key":"2774_CR22","unstructured":"U.S. Food and Drug Administration (2025) FDA approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-enfortumab-vedotin-ejfv-muscle-invasive-bladder-cancer"},{"key":"2774_CR23","doi-asserted-by":"crossref","unstructured":"Necchi A, Guerrero-Ramos F, Crispen PL et\u00a0al. (2025) TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a\u00a0randomised, open-label phase\u00a02\u00a0trial. Lancet Oncol 26:1312\u20131322","DOI":"10.1016\/S1470-2045(25)00358-4"},{"key":"2774_CR24","doi-asserted-by":"crossref","unstructured":"Peyton CC, Tang D, Reich RR et\u00a0al. (2018) Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer. JAMA Oncol 4:1535\u20131542","DOI":"10.1001\/jamaoncol.2018.3542"},{"key":"2774_CR25","doi-asserted-by":"crossref","unstructured":"Laukhtina E, Moschini M, Teoh JY et\u00a0al. (2024) Bladder sparing options for muscle-invasive bladder cancer. Curr Opin Urol 34:471\u2013476","DOI":"10.1097\/MOU.0000000000001220"},{"key":"2774_CR26","doi-asserted-by":"publisher","unstructured":"Eturi A, Bhasin A, Zarrabi KK et al. (2024) Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma. Molecules 29 (8); https:\/\/doi.org\/10.3390\/molecules29081896","DOI":"10.3390\/molecules29081896"},{"key":"2774_CR27","doi-asserted-by":"crossref","unstructured":"Loriot Y, Matsubara N, Park SH et\u00a0al. (2023) Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 389:1961\u20131971","DOI":"10.1056\/NEJMoa2308849"},{"key":"2774_CR28","doi-asserted-by":"crossref","unstructured":"Gray PJ, Lin CC, Jemal A et\u00a0al. (2014) Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. Int J Radiat Oncol Biol Phys 88:1048\u20131056","DOI":"10.1016\/j.ijrobp.2014.01.001"},{"key":"2774_CR29","doi-asserted-by":"crossref","unstructured":"Rink M, Babjuk M, Catto JW et\u00a0al. (2013) Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a\u00a0critical review of the current literature. Eur Urol 64:624\u2013638","DOI":"10.1016\/j.eururo.2013.07.007"},{"key":"2774_CR30","doi-asserted-by":"crossref","unstructured":"Cowan ML, Vandenbussche CJ (2018) The Paris System for Reporting Urinary Cytology: early review of the literature reveals successes and rare shortcomings. J\u00a0Am Soc Cytopathol 7:185\u2013194","DOI":"10.1016\/j.jasc.2018.04.001"},{"key":"2774_CR31","doi-asserted-by":"crossref","unstructured":"Harrs CF, Pusala S, Cheng L et\u00a0al. (2026) Recent advances in liquid biopsy for genitourinary cancers: A\u00a0narrative review. Histopathology 88:338\u2013352","DOI":"10.1111\/his.70047"},{"key":"2774_CR32","doi-asserted-by":"crossref","unstructured":"Galior KD, Baumann NA (2020) Challenges with At-home and Mail-in Direct-to-Consumer Testing: Preanalytical Error, Reporting Results, and Result Interpretation. Clin Lab Med 40:25\u201336","DOI":"10.1016\/j.cll.2019.11.006"},{"key":"2774_CR33","doi-asserted-by":"crossref","unstructured":"Lindskrog SV, Birkenkamp-Demtroder K, Nordentoft I et\u00a0al. (2023) Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up. Clin Cancer Res 29:4797\u20134807","DOI":"10.1158\/1078-0432.CCR-23-1860"},{"key":"2774_CR34","doi-asserted-by":"crossref","unstructured":"Nandi D, Kumar SK, Hasan A et\u00a0al. (2025) Diagnostic accuracy of the Vesical Imaging Reporting and Data System for muscle-invasive bladder cancer and its role in reducing repeat transurethral resection of bladder tumor: A\u00a0systematic review. Bladder (San Franc) 12:e21200065","DOI":"10.14440\/bladder.0022"},{"key":"2774_CR35","doi-asserted-by":"crossref","unstructured":"Dehghanpour A, Pecoraro M, Messina E et\u00a0al. (2025) Diagnostic accuracy and inter-reader agreement of the nacVI-RADS for bladder cancer treated with neoadjuvant chemotherapy: a\u00a0prospective validation study. Eur Radiol 35:4016\u20134026","DOI":"10.1007\/s00330-024-11327-w"},{"key":"2774_CR36","doi-asserted-by":"publisher","unstructured":"Panebianco V, Briganti A, Efstathiou JA et al. (2025) Multiparametric Magnetic Resonance Imaging and Vesical Imaging-Reporting and Data System (VI-RADS) for Bladder Cancer Diagnosis and Staging: A Guide for Clinicians fromthe American College of RadiologyV I-RADS Steering Committee.  Eur Urol; Epub date 2025\/11\/02; https:\/\/doi.org\/10.1016\/j.eururo.2025.10.010","DOI":"10.1016\/j.eururo.2025.10.010"},{"key":"2774_CR37","doi-asserted-by":"crossref","unstructured":"Brembilla G, Basile G, Cosenza M et\u00a0al. (2024) Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI. Radiology 313:e233020","DOI":"10.1148\/radiol.233020"},{"key":"2774_CR38","doi-asserted-by":"crossref","unstructured":"Ditonno F, Veccia A, Montanaro F et\u00a0al. (2024) Trimodal therapy vs radical cystectomy in patients with muscle-invasive bladder cancer: a\u00a0systematic review and meta-analysis of comparative studies. BJU Int 134:684\u2013695","DOI":"10.1111\/bju.16366"},{"key":"2774_CR39","doi-asserted-by":"crossref","unstructured":"Zimmermann K, Mostafaei H, Heidenreich A et\u00a0al. (2021) Health-related quality of life in bladder cancer patients: general and cancer-specific instruments. Part\u00a01. Curr Opin Urol 31:297\u2013303","DOI":"10.1097\/MOU.0000000000000893"},{"key":"2774_CR40","doi-asserted-by":"crossref","unstructured":"Vulsteke C, Kaimakliotis H, Danchaivijitr P et al. (2025) Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase III KEYNOTE-905 study.","DOI":"10.1016\/j.annonc.2025.09.124"},{"key":"2774_CR41","doi-asserted-by":"crossref","unstructured":"Hahn O, Kubler H (2025) [Bladder sparing options for muscle invasive high risk bladder cancer]. Aktuelle Urol 56:340\u2013343.","DOI":"10.1055\/a-2586-5554"},{"key":"2774_CR42","unstructured":"https:\/\/icons8.de\/icons\/set\/chemotherapy (open source)."}],"updated-by":[{"DOI":"10.1007\/s00120-026-02807-6","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000}}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02774-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-026-02774-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02774-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:33:59Z","timestamp":1773297239000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-026-02774-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2774"],"URL":"https:\/\/doi.org\/10.1007\/s00120-026-02774-y","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"11 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Die Originalversion dieses Artikels wurde korrigiert: Verschiedene Referenzen wurden erg\u00e4nzt.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Der Originalbeitrag wurde korrigiert: In diesem Artikel wurde die Erkl\u00e4rung zum Interessenkonflikt f\u00e4lschlicherweise mit \u201eC. Bolenz, F. Zengerling, H. K\u00fcbler und O. Hahn geben an, dass kein Interessenkonflikt besteht.\u201c angegeben.","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Richtig ist \u201eC. Bolenz: Honorare f\u00fcr Vortrags- und Beratert\u00e4tigkeiten sowie Forschungsf\u00f6rderung: Astra Zeneca, Bayer, Bristol-Myers Squibb, Cepheid, ERBE, Ferring, Johnson&Johnson, MSD. F. Zengerling: Honorare f\u00fcr Vortrags- und Beratert\u00e4tigkeiten: Astra Zeneca, Astellas, Bristol-Myers Squibb, Daiichi Sankyo, Johnson&Johnson, Merck, MSD, Pfizer, Roche. H. K\u00fcbler: keine. O. Hahn: Honorare f\u00fcr Vortrags- und Beratert\u00e4tigkeiten: AstraZeneca, Bayer, Boston Scientific, Johnson&Johnson, Medtronic, Pierre Fabre, Promedon.\u201c","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":12,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":13,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Zu diesem Beitrag wurde ein Erratum ver\u00f6ffentlicht:","order":14,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00120-026-02807-6","URL":"https:\/\/doi.org\/10.1007\/s00120-026-02807-6","order":15,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Bolenz: Honorare f\u00fcr Vortrags- und Beratert\u00e4tigkeiten sowie Forschungsf\u00f6rderung: Astra Zeneca, Bayer, Bristol-Myers Squibb, Cepheid, ERBE, Ferring, Johnson&Johnson, MSD. F.\u00a0Zengerling: Honorare f\u00fcr Vortrags- und Beratert\u00e4tigkeiten: Astra Zeneca, Astellas, Bristol-Myers Squibb, Daiichi Sankyo, Johnson&Johnson, Merck, MSD, Pfizer, Roche. H.\u00a0K\u00fcbler: keine. O.\u00a0Hahn: Honorare f\u00fcr Vortrags- und Beratert\u00e4tigkeiten: AstraZeneca, Bayer, Boston Scientific, Johnson&Johnson, Medtronic, Pierre Fabre, Promedon.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}